What is HC Wainwright’s Forecast for IPSEN FY2026 Earnings?

IPSEN (OTCMKTS:IPSEY) – Stock analysts at HC Wainwright issued their FY2026 earnings per share (EPS) estimates for shares of IPSEN in a note issued to investors on Friday, June 5th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings of $3.49 per share for the year. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for IPSEN’s current full-year earnings is $4.05 per share. HC Wainwright also issued estimates for IPSEN’s FY2027 earnings at $3.92 EPS.

A number of other research analysts have also recently weighed in on IPSEY. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of IPSEN in a research report on Thursday, May 14th. Zacks Research raised IPSEN to a “hold” rating in a research report on Friday, May 29th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold”.

IPSEN Stock Up 3.8%

IPSEY stock opened at $46.75 on Tuesday. IPSEN has a twelve month low of $28.66 and a twelve month high of $51.10. The business’s 50-day moving average price is $47.87 and its 200-day moving average price is $42.78.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).